Business Context and Reporting Period
Company: Gain Therapeutics, Inc. (GANX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2025
Reporting Period: The filing addresses a specific compliance event occurring between November 14, 2024, and December 27, 2024, with resolution confirmed on January 15, 2025.
Key Financial Metrics
This filing does not contain standard financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding listing standards.
Material Changes
- Listing Deficiency: The Company received a notice from Nasdaq on January 8, 2025, stating that its Market Value of Listed Securities (MVLS) fell below the required $50 million minimum from November 14, 2024, to December 27, 2024.
- Compliance Status: As of January 14, 2025, the Company regained compliance with the MVLS Requirement. Nasdaq staff provided written confirmation of compliance on January 15, 2025.
- Trading Status: The deficiency notice had no immediate effect on trading; common stock continued to trade on the Nasdaq Global Market under the symbol "GANX" throughout the period.
Outlook, Risks, and Management Commentary
Management Commentary: The filing confirms the matter is now closed following the receipt of written confirmation from Nasdaq. There is no forward-looking guidance or discussion of operational risks beyond the specific listing standard issue.
Risks: The primary risk identified was the potential delisting due to failure to meet the $50 million MVLS threshold, which has been resolved.
Investor Verification Checklist
- Verify the current Market Value of Listed Securities (MVLS) to ensure it remains above the $50 million threshold.
- Confirm the stock continues to trade on the Nasdaq Global Market under ticker GANX.
- Review subsequent filings for any recurrence of listing deficiencies or new compliance notices.